Format

Send to

Choose Destination
PLoS One. 2015 Jul 16;10(7):e0133219. doi: 10.1371/journal.pone.0133219. eCollection 2015.

Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

Author information

1
Oregon Health Sciences University, Department of Biomedical Engineering, Portland, Oregon, United States of America.
2
University of California San Francisco, Division of Heme/Onc, San Francisco, California, United States of America.
3
Netherlands Cancer Institute, Division of Biochemistry, Amsterdam, The Netherlands; University of Warwick, Centre for Complexity Science, Coventry, United Kingdom.
4
Lawrence Berkeley National Laboratories, Life Sciences Division, Berkeley, California, United States of America.
5
University of California, Berkeley, Department of Electrical Engineering and Computer Sciences, Berkeley, California, United States of America.
6
Oregon Health Sciences University, Department of Biomedical Engineering, Portland, Oregon, United States of America; Lawrence Berkeley National Laboratories, Life Sciences Division, Berkeley, California, United States of America.
7
MD Anderson Cancer Center, Department of Systems Biology, Houston, Texas, United States of America.
8
Netherlands Cancer Institute, Division of Biochemistry, Amsterdam, The Netherlands.

Abstract

We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2(+) breast cancers. We accomplished this by measuring cellular and molecular responses to lapatinib and the AKT inhibitors (AKTi) GSK690693 and GSK2141795 in a panel of 22 HER2(+) breast cancer cell lines carrying wild type or mutant PIK3CA. We observed that combinations of lapatinib plus AKTi were synergistic in HER2(+)/PIK3CA(mut) cell lines but not in HER2(+)/PIK3CA(wt) cell lines. We measured changes in phospho-protein levels in 15 cell lines after treatment with lapatinib, AKTi or lapatinib + AKTi to shed light on the underlying signaling dynamics. This revealed that p-S6RP levels were less well attenuated by lapatinib in HER2(+)/PIK3CA(mut) cells compared to HER2(+)/PIK3CAwt cells and that lapatinib + AKTi reduced p-S6RP levels to those achieved in HER2(+)/PIK3CA(wt) cells with lapatinib alone. We also found that that compensatory up-regulation of p-HER3 and p-HER2 is blunted in PIK3CA(mut) cells following lapatinib + AKTi treatment. Responses of HER2(+) SKBR3 cells transfected with lentiviruses carrying control or PIK3CA(mut )sequences were similar to those observed in HER2(+)/PIK3CA(mut) cell lines but not in HER2(+)/PIK3CA(wt) cell lines. We used a nonlinear ordinary differential equation model to support the idea that PIK3CA mutations act as downstream activators of AKT that blunt lapatinib inhibition of downstream AKT signaling and that the effects of PIK3CA mutations can be countered by combining lapatinib with an AKTi. This combination does not confer substantial benefit beyond lapatinib in HER2+/PIK3CA(wt) cells.

PMID:
26181325
PMCID:
PMC4504492
DOI:
10.1371/journal.pone.0133219
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center